Concomitant expression of hepatocyte growth factor scatter factor and the receptor c-MET in human myeloma cell lines

被引:116
作者
Borset, M
Lien, E
Espevik, T
Helseth, E
Waage, A
Sundan, A
机构
[1] Inst. Cancer Res./Molec. Biology, Norwegian Univ. of Technol./Science, Medisinsk Teknisk Senter
[2] Dept. of Neurosurgery, Rikshospitalet, Oslo
关键词
D O I
10.1074/jbc.271.40.24655
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloma cell line supernatants were screened for their ability to inhibit the activity of transforming growth factor-beta (TGF beta) in the mink lung cell (Mv-1-Lu) bioassay. Supernatant from the human myeloma cell line JJN-3 contained potent TGF beta antagonistic activity. This activity was isolated and found to be associated with a 72-78-kDa glycoprotein. Specific polyclonal and monoclonal antibodies were generated toward the 72-78-kDa protein, and these antibodies precipitated the TGF beta inhibitory activity from JJN-3 supernatant. Upon amino acid sequencing the protein appeared to be identical to hepatocyte growth factor (HGF), and some of the generated antibodies directly blocked the action of recombinant HGF in various assays. By HGF-specific polymerase chain reaction we demonstrated that HGF mRNA was expressed in five out of five tested myeloma cell lines. The level of HGF protein in supernatants showed great variation from >500 ng/ml in JJN-3 supernatant to a few ng/ml in the supernatants from other myeloma cell lines. The same five cell lines were also screened for expression the HGF receptor c-MET. Four of them expressed the receptor as shown by reverse transcriptase-polymerase chain reaction and Western blot. The receptor was shown to be constitutively phosphorylated in the human myeloma cell line JJN-3. This receptor could be dephosphorylated by anti-HGF antibodies, indicating the existence of an autocrine HGF loop in this cell line. We propose that HGF/c-MET may play a role in multiple myeloma.
引用
收藏
页码:24655 / 24661
页数:7
相关论文
共 49 条
[1]   MECHANISMS OF BONE DESTRUCTION IN MULTIPLE-MYELOMA - THE IMPORTANCE OF AN UNBALANCED PROCESS IN DETERMINING THE SEVERITY OF LYTIC BONE-DISEASE [J].
BATAILLE, R ;
CHAPPARD, D ;
MARCELLI, C ;
DESSAUW, P ;
SANY, J ;
BALDET, P ;
ALEXANDRE, C .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1909-1914
[2]  
BATAILLE R, 1990, CANCER-AM CANCER SOC, V66, P167, DOI 10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO
[3]  
2-9
[4]  
BELLUSCI S, 1994, ONCOGENE, V9, P1091
[5]  
BORSET M, 1994, EUR J HAEMATOL, V53, P31
[6]   Hepatocyte growth factor reverses the TGF-beta-induced growth inhibition of CCL-64 cells - A novel bioassay for HGF and implications for the TGF-beta bioassay [J].
Borset, M ;
Waage, A ;
Sundan, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 189 (01) :59-64
[7]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[8]   HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH [J].
BUSSOLINO, F ;
DIRENZO, MF ;
ZICHE, M ;
BOCCHIETTO, E ;
OLIVERO, M ;
NALDINI, L ;
GAUDINO, G ;
TAMAGNONE, L ;
COFFER, A ;
COMOGLIO, PM .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :629-641
[9]  
CLARK MR, 1981, METHOD ENZYMOL, V73, P12
[10]  
Comoglio P M, 1993, EXS, V65, P131